These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 19405217)

  • 21. Moraxella catarrhalis-produced nitric oxide has dual roles in pathogenicity and clearance of infection in bacterial-host cell co-cultures.
    Mocca B; Yin D; Gao Y; Wang W
    Nitric Oxide; 2015 Dec; 51():52-62. PubMed ID: 26537639
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular pathogenesis of infections caused by Moraxella catarrhalis in children.
    Bernhard S; Spaniol V; Aebi C
    Swiss Med Wkly; 2012; 142():w13694. PubMed ID: 23136074
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sulfatide and its synthetic analogues recognition by Moraxella catarrhalis.
    Ozcelik P; Bezirci FB; Suzuki Y; Uzawa H; Nishida Y; Kobayashi K; Suzuki T; Miyamoto D; Nagatake T; Ahmed K
    Microbiol Immunol; 2006; 50(12):967-70. PubMed ID: 17179664
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence of Moraxella catarrhalis infections of the lower respiratory tract in elderly patients.
    Tamang MD; Dey S; Makaju RK; Jha BK; Shivananda PG; Bhramadatan KN
    Kathmandu Univ Med J (KUMJ); 2005; 3(1):39-44. PubMed ID: 16401943
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Moraxella catarrhalis: a review of an important human mucosal pathogen.
    Karalus R; Campagnari A
    Microbes Infect; 2000 Apr; 2(5):547-59. PubMed ID: 10865200
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of Moraxella (Branhamella) catarrhalis as a respiratory pathogen in children.
    Korppi M; Katila ML; Jääskeläinen J; Leinonen M
    Acta Paediatr; 1992 Dec; 81(12):993-6. PubMed ID: 1290865
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current progress of adhesins as vaccine candidates for Moraxella catarrhalis.
    Tan TT; Riesbeck K
    Expert Rev Vaccines; 2007 Dec; 6(6):949-56. PubMed ID: 18377357
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Moraxella catarrhalis Evades Host Innate Immunity via Targeting Cartilage Oligomeric Matrix Protein.
    Liu G; Gradstedt H; Ermert D; Englund E; Singh B; Su YC; Johansson ME; Aspberg A; Agarwal V; Riesbeck K; Blom AM
    J Immunol; 2016 Feb; 196(3):1249-58. PubMed ID: 26712944
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Moraxella catarrhalis coaggregates with Streptococcus pyogenes and modulates interactions of S. pyogenes with human epithelial cells.
    Lafontaine ER; Wall D; Vanlerberg SL; Donabedian H; Sledjeski DD
    Infect Immun; 2004 Nov; 72(11):6689-93. PubMed ID: 15501804
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Age-related genotypic and phenotypic differences in Moraxella catarrhalis isolates from children and adults presenting with respiratory disease in 2001-2002.
    Verhaegh SJC; Streefland A; Dewnarain JK; Farrell DJ; van Belkum A; Hays JP
    Microbiology (Reading); 2008 Apr; 154(Pt 4):1178-1184. PubMed ID: 18375810
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Moraxella catarrhalis in chronic and relapsing respiratory tract infections in children].
    Volkov IK; Katosova LK; Shcherbakova NIu; Kliukina LP
    Antibiot Khimioter; 2004; 49(8-9):43-7. PubMed ID: 15727145
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunoinformatics Identifies a Lactoferrin Binding Protein A Peptide as a Promising Vaccine With a Global Protective Prospective Against Moraxella catarrhalis.
    Yassin GM; Amin MA; Attia AS
    J Infect Dis; 2016 Jun; 213(12):1938-45. PubMed ID: 26908723
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Non-susceptibility trends among Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infections in the UK and Ireland, 1999-2007.
    Morrissey I; Maher K; Williams L; Shackcloth J; Felmingham D; Reynolds R;
    J Antimicrob Chemother; 2008 Nov; 62 Suppl 2():ii97-103. PubMed ID: 18819984
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vaccine development for Moraxella catarrhalis: rationale, approaches and challenges.
    Murphy TF
    Expert Rev Vaccines; 2009 Jun; 8(6):655-8. PubMed ID: 19485745
    [No Abstract]   [Full Text] [Related]  

  • 35. Pili play an important role in enhancing the bacterial clearance from the middle ear in a mouse model of acute otitis media with Moraxella catarrhalis.
    Kawano T; Hirano T; Kodama S; Mitsui MT; Ahmed K; Nishizono A; Suzuki M
    Pathog Dis; 2013 Mar; 67(2):119-31. PubMed ID: 23620157
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence and emerging resistance of Moraxella catarrhalis in lower respiratory tract infections in Karachi.
    Abdullah FE; Ahuja KR; Kumar H
    J Pak Med Assoc; 2013 Nov; 63(11):1342-4. PubMed ID: 24392515
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The respiratory pathogen moraxella catarrhalis binds to laminin via ubiquitous surface proteins A1 and A2.
    Tan TT; Forsgren A; Riesbeck K
    J Infect Dis; 2006 Aug; 194(4):493-7. PubMed ID: 16845633
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Virulence determinants of Moraxella catarrhalis: distribution and considerations for vaccine development.
    Blakeway LV; Tan A; Peak IRA; Seib KL
    Microbiology (Reading); 2017 Oct; 163(10):1371-1384. PubMed ID: 28893369
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vaccines for Moraxella catarrhalis.
    McMichael JC
    Vaccine; 2000 Dec; 19 Suppl 1():S101-7. PubMed ID: 11163472
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Moraxella catarrhalis bacterium without endotoxin, a potential vaccine candidate.
    Peng D; Hong W; Choudhury BP; Carlson RW; Gu XX
    Infect Immun; 2005 Nov; 73(11):7569-77. PubMed ID: 16239560
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.